EGFR Inhibitors

2 articles · search the full text for this term

• Published Subscription Review Article 2 Jun 2026

  Non-Small Cell Lung Cancer: Types, Pathogenesis, Diagnosis, and Novel Therapeutic Strategies

  By Nandini Rajendra Jadhav, Dipti R. Rajput, Devyani V. Dhangar, Puja R. Chavhn

  Abstract: Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer, accounting for over 85% of all cases globally. It remains one of the primary causes of cancer-related death due to its rapid progression, few early symptoms, and late detection. The three main forms of non-small cell lung cancer (NSCLC) are adenocarcinoma, squamous cell carcinoma, and giant cell carcinoma; each has a unique histology, prognosis, and response to …

  Published in Research and Reviews: A Journal of Pharmacology · Vol. 16, Issue 2, 2026 Read article →

• Published Subscription Review Article 7 Apr 2026

  Mass Spectrometry–Based Phosphoproteomic Markers to Predict Kinase Inhibitor Response in Solid Tumors

  By Atul Khajuria, Ashish Kumar

  Abstract: Mass spectrometry-based phosphoproteomics has emerged as a powerful tool for predicting kinase inhibitor responses in solid tumors, offering direct functional insights into signaling pathways that surpass traditional genomic profiling by capturing dynamic kinase activities and adaptive resistance mechanisms. Technological breakthroughs, including data- independent acquisition (DIA), trapped ion mobility spectrometry (timsTOF), and efficient enrichment methods like TiO2 or IMAC, now enable comprehensive profiling of over 40,000 phosphorylation sites from limited clinical …

  Published in International Journal of Cell Biology and Cellular Functions · Vol. 4, Issue 2, 2026 Read article →